198 related articles for article (PubMed ID: 11668500)
21. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
22. [Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors].
Loginov VI; Maliukova AV; Seregin IuA; Khodyrev DS; Kazubskaia TP; Ermilova VD; Gar'kavtseva RF; Kiselev LL; Zabarovskiĭ ER; Braga EA
Mol Biol (Mosk); 2004; 38(4):654-67. PubMed ID: 15456137
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
Burbee DG; Forgacs E; Zöchbauer-Müller S; Shivakumar L; Fong K; Gao B; Randle D; Kondo M; Virmani A; Bader S; Sekido Y; Latif F; Milchgrub S; Toyooka S; Gazdar AF; Lerman MI; Zabarovsky E; White M; Minna JD
J Natl Cancer Inst; 2001 May; 93(9):691-9. PubMed ID: 11333291
[TBL] [Abstract][Full Text] [Related]
24. [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas].
Hong FZ; Wang B; Li HM; Liew CT
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):257-61. PubMed ID: 16181544
[TBL] [Abstract][Full Text] [Related]
25. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
26. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
[TBL] [Abstract][Full Text] [Related]
27. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.
Dammann R; Schagdarsurengin U; Liu L; Otto N; Gimm O; Dralle H; Boehm BO; Pfeifer GP; Hoang-Vu C
Oncogene; 2003 Jun; 22(24):3806-12. PubMed ID: 12802288
[TBL] [Abstract][Full Text] [Related]
28. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
30. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
31. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
32. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
33. The tumor suppressor RASSF1A in human carcinogenesis: an update.
Dammann R; Schagdarsurengin U; Seidel C; Strunnikova M; Rastetter M; Baier K; Pfeifer GP
Histol Histopathol; 2005 Apr; 20(2):645-63. PubMed ID: 15736067
[TBL] [Abstract][Full Text] [Related]
34. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection.
Kuzmin I; Liu L; Dammann R; Geil L; Stanbridge EJ; Wilczynski SP; Lerman MI; Pfeifer GP
Cancer Res; 2003 Apr; 63(8):1888-93. PubMed ID: 12702579
[TBL] [Abstract][Full Text] [Related]
35. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers.
Hesson L; Dallol A; Minna JD; Maher ER; Latif F
Oncogene; 2003 Feb; 22(6):947-54. PubMed ID: 12584574
[TBL] [Abstract][Full Text] [Related]
36. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.
Schagdarsurengin U; Wilkens L; Steinemann D; Flemming P; Kreipe HH; Pfeifer GP; Schlegelberger B; Dammann R
Oncogene; 2003 Mar; 22(12):1866-71. PubMed ID: 12660822
[TBL] [Abstract][Full Text] [Related]
37. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
38. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
39. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis.
Dammann R; Schagdarsurengin U; Strunnikova M; Rastetter M; Seidel C; Liu L; Tommasi S; Pfeifer GP
Histol Histopathol; 2003 Apr; 18(2):665-77. PubMed ID: 12647816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]